2. Search Result
Search Result
Isoforms Recommended: PAK4
Results for "

PAK4

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Natural
Products

3

Recombinant Proteins

4

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13007
    PF-3758309
    5+ Cited Publications

    PF-03758309

    		 PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309
  • HY-15663
    IPA-3
    Maximum Cited Publications
    17 Publications Verification

    		 PAK Cancer
    IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, and shows no inhibition to group II PAKs (PAKs 4-6).
    IPA-3
  • HY-12793
    Padnarsertib
    3 Publications Verification

    KPT-9274

    		 PAK NAMPT Cancer
    Padnarsertib (KPT-9274) is an orally bioavailable, dual PAK4/Nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with IC50s of <100 nM and 120 nM, respectively .
    Padnarsertib
  • HY-12632
    GNE 2861
    2 Publications Verification

    		 PAK Cancer
    GNE 2861 is a PAK inhibitor that displays group II selectivity. GNE 2861 inhibits PAK4, PAK5 and PAK6 with IC50s of 7.5, 36, 126 nM, respectively.
    GNE 2861
  • HY-19538
    FRAX1036
    5 Publications Verification

    		 PAK Cancer
    FRAX1036 is a PAK inhibitor with Kis of 23.3 nM, 72.4 nM, and 2.4 μM for PAK1, PAK2 and PAK4, respectively.
    FRAX1036
  • HY-125035
    LCH-7749944
    5 Publications Verification

    GNF-PF-2356

    		 PAK Apoptosis Cancer
    LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor with an IC50 of 14.93 μM. LCH-7749944 effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclin D1 pathway and induces apoptosis .
    LCH-7749944
  • HY-143490
    PAK4-IN-2

    		PAK Apoptosis Cancer
    PAK4-IN-2 is a highly potent PAK4 inhibitor with IC50 value of 2.7 nM. PAK4-IN-2 can arrest MV4-11 cells at G0/G1 phase and induce cell apoptosis. PAK4-IN-2 can be used for researching cancer .
    PAK4-IN-2
  • HY-114331
    DLK-IN-1

    		MAP3K FLT3 PAK STK33 Trk Receptor Neurological Disease
    DLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research .
    DLK-IN-1
  • HY-N8389
    Globulol

    		Bacterial Fungal PAK Akt STAT PD-1/PD-L1 Apoptosis CCR Infection Cancer
    Globulol is a terpenoid metabolite and Antimicrobial agent. Globulol can be isolated from Alpinia oxyphylla Miq. Globulol binds to PAK4, reduces the expression level of PAK4 in cancer cells, decreases the phosphorylation of AKT, and downregulates the expressions of STAT3, phosphorylated STAT3, and PD-L1. Globulol promotes the secretion of CCL4 by cancer cells. Globulol reduces the viability and proliferation ability of cancer cells, induces G0/G1 cell cycle arrest and Apoptosis in cancer cells, and inhibits cancer cell migration and the integrity of 3D tumor spheres. Globulol enhances the relevant effects of anti-PD-1 agents in the cancer cell microenvironment. Globulol exhibits anticancer activity against liver cancer. Globulol inhibits the mycelial growth of phytopathogenic fungi and the growth of phytopathogenic bacteria. Globulol can be used in studies related to hepatocellular carcinoma .
    Globulol
  • HY-174247
    CPS-021

    		PROTACs PAK Cadherin Cancer
    CPS-021 is a selective PAK4 PROTAC degrader with a DC50 of 50 nM. CPS-021 has potent antimigratory and invasive activity and significantly suppresses the invasion and metastasis of tumor cells in A549-luc lung metastasis mice model . Pink: PAK4 ligand (HY-174822); Blue: CRBN ligase ligand (HY-10984); Black: linker
    CPS-021
  • HY-130628
    PAK4-IN-1

    		PAK Cancer
    PAK4-IN-1 (Compound 19) is a potent, selective, orally active PAK4 inhibitor with robust anti-tumor efficacy in vivo. PAK4-IN-1 is stable under both acidic and neutral conditions .
    PAK4-IN-1
  • HY-RS09995
    Pak4 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Pak4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pak4 Rat Pre-designed siRNA Set A
    Pak4 Rat Pre-designed siRNA Set A
  • HY-RS09994
    Pak4 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) PAK Others

    Pak4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pak4 Mouse Pre-designed siRNA Set A
    Pak4 Mouse Pre-designed siRNA Set A
  • HY-RS09993
    PAK4 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) PAK Others

    PAK4 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PAK4 Human Pre-designed siRNA Set A
    PAK4 Human Pre-designed siRNA Set A
  • HY-159897
    PAK4-IN-5

    		PAK LIM Kinase (LIMK) Apoptosis Reactive Oxygen Species (ROS) Cancer
    PAK4-IN-5 (Compound 12i) is a PAK4 inhibitor (IC50: 7.68 nM for PAK4, 1872.01 nM for PAK1). PAK4-IN-5 binds to PAK4 stably via multiple interactions. PAK4-IN-5 inhibits the proliferation and the migratory potential of MDA-MB-231 cells by inhibiting the phosphorylation of PAK4 and LIMK1. PAK4-IN-5 arrests cell cycle in the G0/G1 phase, induces apoptosis and ROS production. LD50: >500 mg/kg for mice (p.o.) .
    PAK4-IN-5
  • HY-174822
    PAK4-IN-6

    		Ligands for Target Protein for PROTAC PAK Others
    PAK4-IN-6 is a selective degrader of PAK4. PAK4-IN-6 can be used to synthesize PROTACs such as CPS-021 (HY-174247) .
    PAK4-IN-6
  • HY-117218
    KY-04045

    		PAK Cancer
    KY-04045 is a PAK4 specific inhibitor (IC50=8.7 μM) that can be used for the development of anticancer drugs targeting PAK4 .
    KY-04045
  • HY-124764
    KY-04031

    		PAK Cancer
    KY-04031 is a potent PAK4 inhibitor with IC50 of 0.79 μM. KY-04031 binds to the ATP-binding pocket of PAK4. KY-04031 blocks tumor cell growth and invasion .
    KY-04031
  • HY-124398
    GL-1196

    		PAK Cancer
    GL-1196 is an inhibitor of PAK4. GL-1196 can suppress the proliferation and invasion of gastric cancer cells. GL-1196 inhibits PAK4-mediated signaling pathways. GL-1196 can hinder the proliferation of human gastric cancer cells through suppressing PAK4/c-Src/EGFR/CyclinD1 and CDK4/6. GL-1196 can reduce filamentous pseudopodia formation and induce filamentous pseudopodia formation and promote cell elongation in SGC7901 and BGC823 cells. GL-1196 can be studied in anti-cancer research .
    GL-1196
  • HY-13007A
    PF-3758309 hydrochloride

    PF-03758309 hydrochloride

    		 PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309 hydrochloride
  • HY-13007B
    PF-3758309 dihydrochloride

    PF-03758309 dihydrochloride

    		 PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309 dihydrochloride
  • HY-156453
    PAK4-IN-3

    		PAK Apoptosis Cancer
    PAK4-IN-3(compound 27e) is aPAK4inhibitor, with theIC50of 10 nM.PAK4-IN-3shows antiproliferative activity against A549 cells with anIC50value of 0.61μM, and inducesapoptosisof A549 cells in a concentration-dependent manner and blocked the cell cycle at phase G0/G1 .
    PAK4-IN-3
  • HY-181092
    PAK4-IN-7

    		PAK Cancer
    PAK4-IN-7 is a selective ATP-competitive inhibitor of p21-activated kinase 4 (PAK4), with an IC50 of 1.88 μM. PAK4-IN-7 inhibits the proliferation of cancer cells. PAK4-IN-7 is applicable for research on tumors such as colorectal cancer and lung cancer .
    PAK4-IN-7
  • HY-174248
    PS21M

    		PROTACs PAK Cancer
    PS21M is a negative control of CPS-021 (HY-174247). PS21M cannot effectively degrade PAK4 in MDA-MB-231 cells. (Pink: Target Protein Ligand (HY-174822); Black: Linker; Blue: E3 Ligase Ligand (HY-W586822)) .
    PS21M
  • HY-15663R
    IPA-3 (Standard)

    		PAK Cancer
    IPA-3 (Standard) is the analytical standard of IPA-3. This product is intended for research and analytical applications. IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, and shows no inhibition to group II PAKs (PAKs 4-6).
    IPA-3 (Standard)
  • HY-111103A
    CZh226 hydrochloride

    		PAK Cancer
    CZh226 hydrochloride is a potent and selective PAK4 inhibitor with an IC50 of 18 nM, and its selectivity for PAK1 is 346 times. The oral bioavailability of CZh226 hydrochloride is poor, and it requires the use of the prodrug PAK4-IN-1 (HY-130628) to improve absorption and metabolic stability. CZh226 hydrochloride can be used for research on colorectal cancer and melanoma .
    CZh226 hydrochloride
  • HY-111103
    CZh226

    		PAK LIM Kinase (LIMK) MMP Cancer
    CZh226 is a selective PAK4 inhibitor with an IC50 of 0.0111 μM and a Ki of 0.009 μM. CZh226 functionally inhibits PAK4 activity and reduces the phosphorylation level of downstream signaling molecules. CZh226 inhibits the migration and invasion of tumor cells. CZh226 is applicable to lung cancer-related research .
    CZh226
  • HY-182357
    PAK1-IN-3

    		PAK Potassium Channel Others
    PAK1-IN-3 is a PAK1 inhibitor with an IC50 of 10 nM, an IC50 of 20 nM against PAK2, and an IC50 of 1079 nM against hERG potassium channels. PAK1-IN-3 forms a salt bridge with Asp106 in PAK1 via a properly positioned tertiary amine. PAK1-IN-3 inhibits PAK2 and hERG potassium channels .
    PAK1-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: